RXi Pharmaceuticals Corporation (RXII) Analysts See $-0.96 EPS

March 18, 2018 - By Marguerite Chambers

 RXi Pharmaceuticals Corporation (RXII) Analysts See $ 0.96 EPS

Analysts expect RXi Pharmaceuticals Corporation (NASDAQ:RXII) to report $-0.96 EPS on March, 29.They anticipate $5.04 EPS change or 84.00 % from last quarter’s $-6 EPS. After having $-1.10 EPS previously, RXi Pharmaceuticals Corporation’s analysts see -12.73 % EPS growth. The stock increased 5.69% or $0.29 during the last trading session, reaching $5.39. About 994,240 shares traded or 196.91% up from the average. RXi Pharmaceuticals Corporation (NASDAQ:RXII) has declined 75.22% since March 18, 2017 and is downtrending. It has underperformed by 91.92% the S&P500.

RXi Pharmaceuticals Corporation, a clinical-stage company, focuses on developing therapeutics for unmet medical needs. The company has market cap of $12.77 million. It develops therapies based on its self-delivering RNAi platform; and Samcyprone topical immunomodulatory. It currently has negative earnings. The company's clinical development programs include RXI-109, an sd-rxRNA compound, which is in Phase II clinical trial for preventing or reducing dermal scarring following scar revision surgery of an existing hypertrophic scar; and in Phase I/II clinical trial for treating retinal scarring, as well as in discovery stage for the treatment of corneal scarring.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.